The reverse merger and large PIPE validate Mentari's pipeline and provide ample capital. Monitor shareholder vote (INM requires 2/3 approval) and Nasdaq listing approval. The stock price may reflect the upcoming change in value but carries execution risk until closing.
INM drugs
INM drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 19 $1.60entry
- T+1 · 6mo ago +0.63%α −0.41% · $1.61
- T+5 · 6mo ago +5.63%α +3.38% · $1.69
- T+20 · 5mo ago −6.88%α −7.86% · $1.49
- T+60 · 3mo ago −10.63%α −16.92% · $1.43
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
InMed Pharmaceuticals (INM) entered into a definitive agreement to acquire Mentari Therapeutics via reverse merger, with Mentari shareholders receiving a majority stake in the combined entity. A concurrent PIPE of at least $150 million will fund operations and support the merged company's pipeline. The transaction includes a contingent value right for pre-merger INM shareholders and represents a transformative change of control.
Key Financial Metrics
Key Facts
- Reverse merger: INM acquires Mentari Therapeutics through merger subsidiaries; Mentari shareholders become majority owners of combined entity.
- Mentari valued at $125 million (base Company Equity Value), subject to upward adjustment from PIPE proceeds.
- Concurrent PIPE of at least $150 million from institutional investors, committed via securities purchase agreement.
- Pre-merger INM shareholders receive one CVR per share, entitling them to future contingent payments.
- Combined company to be renamed Mentari Therapeutics, Inc. and will continue trading on Nasdaq.
- New directors and officers from Mentari will take control at closing.
Financial Impact
Mentari base valuation $125M; PIPE adds ≥$150M; combined entity post-money valuation substantially higher than INM's current ~$2M market cap.
Risk Factors
- Failure to obtain required shareholder approval (two-thirds of INM shares).
- Nasdaq listing not granted for combined company.
- PIPE investors may not fund if conditions are not met; termination fee of $4M payable by Mentari if PIPE fails.
- Delays beyond December 31, 2026 end date could terminate deal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-058795 |
| Document: ea029148201ex10-5.htm | 0001213900-26-058795 |
| Document: ea029148201ex10-4.htm | 0001213900-26-058795 |
Track record
22 reports on INM
6 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
- Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
- Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
- Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
- Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
- Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
- Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers